MedTrace Logo

An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)

NCT01019161 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2010-10-20

No results posted yet for this study

Summary

The purpose of the study is to assess how AZD1152 is absorbed or excreted in and out of the body in patients with Acute Myeloid Leukaemia (AML).

Conditions

  • Acute Myeloid Leukaemia

Interventions

DRUG

AZD1152

100mg Lyophile, 5mL Diluent IV infusion

DRUG

C14 AZD1152

radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion

Sponsors & Collaborators

Principal Investigators

  • Mike Dennis, MD · The Christie Hospital, UK

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01019161 on ClinicalTrials.gov